表紙
市場調査レポート

顕微鏡的多発性血管炎(MPA):パイプライン分析

Microscopic Polyangiitis (MPA) - Pipeline Review, H2 2016

発行 Global Markets Direct 商品コード 302487
出版日 ページ情報 英文 47 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.55円で換算しております。
Back to Top
顕微鏡的多発性血管炎(MPA):パイプライン分析 Microscopic Polyangiitis (MPA) - Pipeline Review, H2 2016
出版日: 2016年07月20日 ページ情報: 英文 47 Pages
概要

顕微鏡的多発性血管炎(MPA)は、現在はまだ未知の病であり、血管の炎症の結果として発症し、臓器系に損傷を及ぼします。MPAによる損傷を最も受けやすい部位として、腎臓や肺、神経、皮膚、関節などがあります。主な症状には、息切れや咳、発熱、食欲不振、発疹、筋肉痛・関節痛などが挙げられます。また、主な治療法には免疫抑制療法などがあります。

当レポートでは、世界各国での顕微鏡的多発性血管炎(MPA)治療用のパイプライン製品の開発状況について分析し、パイプライン製品の開発・上市の最新動向や、治験の各段階にある製品の一覧、主要企業のプロファイル、主な薬剤の概要、最新の業界動向などを調査して、その結果を概略以下の構成でお届けします。

目次

イントロダクション

  • 分析範囲

顕微鏡的多発性血管炎の概要

治療薬の開発

  • 顕微鏡的多発性血管炎向けパイプライン製品:概要
  • 顕微鏡的多発性血管炎向けパイプライン製品:比較分析

企業で開発中の治療薬

パイプライン製品の概況

  • 後期段階の製品
  • 臨床段階の製品
  • 初期段階の製品

企業で開発中の製品

治療薬開発に従事している企業

  • Aprogen, Inc.
  • ChemoCentryx, Inc.
  • Epirus Biopharmaceuticals, Inc.
  • GlaxoSmithKline Plc
  • Panacea Biotec Limited
  • Sandoz International GmbH
  • Teijin Pharma Limited

治療薬の評価

  • 単剤製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

  • belimumab
  • CCX-168
  • immune globulin (human)
  • rituximab biosimilar
  • rituximab biosimilar
  • rituximab biosimilar
  • rituximab biosimilar

最新パイプライン動向

休止中のプロジェクト

製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC8259IDB

Summary

Global Markets Direct's, 'Microscopic Polyangiitis (MPA) - Pipeline Review, H2 2016', provides an overview of the Microscopic Polyangiitis (MPA) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Microscopic Polyangiitis (MPA), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Microscopic Polyangiitis (MPA) and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Microscopic Polyangiitis (MPA)
  • The report reviews pipeline therapeutics for Microscopic Polyangiitis (MPA) by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Microscopic Polyangiitis (MPA) therapeutics and enlists all their major and minor projects
  • The report assesses Microscopic Polyangiitis (MPA) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Microscopic Polyangiitis (MPA)

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Microscopic Polyangiitis (MPA)
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Microscopic Polyangiitis (MPA) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
    • Microscopic Polyangiitis (MPA) Overview
    • Therapeutics Development
  • Pipeline Products for Microscopic Polyangiitis (MPA) - Overview
  • Microscopic Polyangiitis (MPA) - Therapeutics under Development by Companies
  • Microscopic Polyangiitis (MPA) - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Microscopic Polyangiitis (MPA) - Products under Development by Companies
  • Microscopic Polyangiitis (MPA) - Companies Involved in Therapeutics Development
    • ChemoCentryx, Inc.
    • Coherus BioSciences, Inc.
    • GlaxoSmithKline Plc
    • Panacea Biotec Limited
    • Sandoz International GmbH
    • Teijin Pharma Limited
  • Microscopic Polyangiitis (MPA) - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • belimumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CCX-168 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • immune globulin (human) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • rituximab biosimilar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • rituximab biosimilar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • rituximab biosimilar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Microscopic Polyangiitis (MPA) - Dormant Projects
  • Microscopic Polyangiitis (MPA) - Product Development Milestones
    • Featured News & Press Releases
      • Dec 04, 2014: ChemoCentryx Granted EU Orphan Drug Designation for CCX168, an Orally Administered Complement C5a Receptor Inhibitor, for the Treatment of Microscopic Polyangiitis and Granulomatosis With Polyangiitis, Two Forms of ANCA-Associated Vasculitis
      • Jun 03, 2014: ChemoCentryx's CCX168, an Orally Administered Complement C5a Receptor Inhibitor, Granted Orphan-Drug Designation in ANCA-Associated Diseases by the FDA
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Microscopic Polyangiitis (MPA), H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Microscopic Polyangiitis (MPA) - Pipeline by ChemoCentryx, Inc., H2 2016
  • Microscopic Polyangiitis (MPA) - Pipeline by Coherus BioSciences, Inc., H2 2016
  • Microscopic Polyangiitis (MPA) - Pipeline by GlaxoSmithKline Plc, H2 2016
  • Microscopic Polyangiitis (MPA) - Pipeline by Panacea Biotec Limited, H2 2016
  • Microscopic Polyangiitis (MPA) - Pipeline by Sandoz International GmbH, H2 2016
  • Microscopic Polyangiitis (MPA) - Pipeline by Teijin Pharma Limited, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Microscopic Polyangiitis (MPA) - Dormant Projects, H2 2016

List of Figures

  • Number of Products under Development for Microscopic Polyangiitis (MPA), H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Targets, H2 2016
  • Number of Products by Stage and Targets, H2 2016
  • Number of Products by Mechanism of Actions, H2 2016
  • Number of Products by Stage and Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top